Stock Movers cover image

Novo Nordisk Up, Vestas Surges, Babcock Rises

Stock Movers

00:00

Intro

This chapter explores the U.S. approval of Novo Nordisk's drug Wagovi for a specific liver disease, marking a pivotal moment for the company. The approval positions Novo Nordisk favorably in a lucrative market, providing a much-needed boost after a challenging year marked by stock declines and competition.

Play episode from 00:00
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app